⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17444796 | 0.72 | — | — | |
| SCHEMBL469416 | 0.67 | — | — | |
| SCHEMBL16221601 | 0.58 | — | — | |
| SCHEMBL14370574 | 0.58 | — | — | |
| SCHEMBL6951658 | 0.58 | — | — | |
| SCHEMBL22091 | 0.52 | — | — | |
| SCHEMBL16072423 | 0.48 | — | — | |
| SCHEMBL12730599 | 0.48 | — | — | |
| SCHEMBL14642132 | 0.48 | — | — | |
| Hydrochloric Acid SCHEMBL743762 | 0.47 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210388359-A1 | OLIGONUCLEOTIDE FORMULATION METHOD | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2021-12-16 | — | — | US | disclosed |
| WO-2020198466-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| EP-3029454-B1 | METHOD FOR EVALUATING HARDNESS OF POLYMER MATERIAL | SUMITOMO RUBBER IND (JP) | 2018-03-14 | — | — | EP | disclosed |
| US-20170020862-A1 | INTRANASAL NALTREXONE | 3B PHARMACEUTICALS INC (US) | 2017-01-26 | — | — | US | disclosed |
| US-20160122400-A1 | POLYPEPTIDES WITH PERMEASE ACTIVITY | DSM IP ASSETS B.V. (NL) | 2016-05-05 | — | — | US | disclosed |
| US-20160068441-A1 | HIGH CORDIERITE-TO-MULLITE RATIO CORDIERITE-MULLITE-ALUMINUM MAGNESIUM TITANATE COMPOSITIONS AND CERAMIC ARTICLES COMPRISING SAME | CORNING INCORPORATED | 2016-03-10 | — | — | US | disclosed |
| EP-2918338-A1 | Process for the production of 1,3-butadiene | LANXESS Deutschland GmbH (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-20140171458-A1 | INTRANASAL NALTREXONE | 3B PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120251453-A1 | Methods and Compositions Related to Annexin 1-Binding Compounds | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-10-04 | — | — | US | disclosed |
| EP-2368877-A1 | Chiral intermediates for the preparation of peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368878-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110118447-A1 | METHODS AND MATERIALS FOR TARGETED AFFINITY ENHANCEMENT | XOMA TECHNOLOGY LTD. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20070027156-A1 | Crf antagonists and heterobicyclic compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |